Get started
NOVONESIS A/S NAM. B DK 2NN

NOVONESIS A/S NAM. B DK 2

62.12EURD
−0.18−0.29%
As of today at 06:03 GMT
EUR
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Forecast Seasonals

NZM2 fundamentals

Key facts

Market capitalization‪28.96 B‬EUR
Dividend yield (indicated)1.34%
Price to earnings Ratio (TTM)94.81
Basic EPS (TTM)0.66EUR
Founded—
Employees (FY)‪10.58 K‬
CEOEster Baiget
Websitenovonesis.com
About

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Ownership
‪‪412.45 M‬‬
Free Float shares
‪‪344.79 M‬‬ (83.6%)
Closely held shares
‪‪67.66 M‬‬ (16.4%)
Free Float shares
‪‪344.79 M‬‬ (83.6%)
Closely held shares
‪‪67.66 M‬‬ (16.4%)
Capital structure
Market cap
‪‪28.96 B‬‬
Debt
‪‪1.70 B‬‬
Cash & equivalents
‪‪256.30 M‬‬
Enterprise value
‪‪30.40 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪28.96 B‬‬
Price to earning ratio (P/E)
94.81x
Price to sales ratio (P/S)
7.60x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
94.81x
Price to sales ratio (P/S)
7.60x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '25
‪0.00‬
‪9.00‬
‪18.00‬
‪27.00‬
‪36.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10%‬
‪13%‬
‪16%‬
‪19%‬
‪22%‬
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '25
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Planetary Health Biosolutions
Food & Health Biosolutions
By country
Period: 2024
Rest of Europe, Middle East & Africa
North America
Asia Pacific
Latin America
Denmark

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
H1 '24
H2 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪550.00 M‬‬
‪‪1.10 B‬‬
‪‪1.65 B‬‬
‪‪2.20 B‬‬
Actual
Estimate
Earnings
Next:Aug 21, 2025
Q4 '23
H1 '24
H2 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
126.14%
Payout ratio (TTM)
Dividend yield TTM
1.33%
Last payment
0.562
Last ex-date
Apr 4, 2025
Last pay date
Apr 8, 2025
Dividend history
‪1.0%‬
‪1.2%‬
‪1.4%‬
‪1.6%‬
‪1.8%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.21‬
‪0.42‬
‪0.63‬
‪0.84‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '25
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Assets
Liabilities